NASDAQ: MREOMereo Biopharma Group PLC Stock
$3.45-0.14 (-3.9%)
Updated May 31, 2024
MREO Price
$3.45
Fair Value Price
-$0.03
Market Cap
$483.94M
52 Week Low
$1.00
52 Week High
$4.36
P/E
N/A
P/B
11.3x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.31
Operating Cash Flow
N/A
Beta
1.07
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MREO Overview
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MREO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MREO ($3.45) is overvalued by 11,110.83% relative to our estimate of its Fair Value price of -$0.03 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MREO ($3.45) is not significantly undervalued (11,110.83%) relative to our estimate of its Fair Value price of -$0.03 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MREO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more MREO due diligence checks available for Premium users.
Be the first to know about important MREO news, forecast changes, insider trades & much more!
MREO News
Valuation
MREO fair value
Fair Value of MREO stock based on Discounted Cash Flow (DCF)
Price
$3.45
Fair Value
-$0.03
Undervalued by
11,110.83%
MREO ($3.45) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MREO ($3.45) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MREO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-14.17x
Market
28.44x
MREO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
11.3x
Industry
6.04x
MREO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MREO's financial health
Profit margin
Revenue
$0.0
Net Income
-$9.0M
Profit Margin
0%
Assets to liabilities
Assets
$55.9M
Liabilities
$13.1M
Debt to equity
0.31
MREO's short-term assets ($53.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MREO's short-term assets ($53.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MREO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.0M
Investing
-$700.0k
Financing
$0.0
MREO vs Biotech Stocks
Mereo Biopharma Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.